Advicenne SA (3MM) AI Stock Analysis

Advicenne SA

(Frankfurt:3MM)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rare-disease specializationAdvicenne’s focus on rare kidney and metabolic diseases gives it a specialized commercial position in areas requiring targeted therapies. This concentration can support differentiated products and durable demand, provided the company continues converting its development expertise into approved and reimbursed sales.

Negative Factors

Small and declining revenue baseA small, volatile revenue base and the reversal to negative growth in 2025 make forward operating performance less predictable. Weak scale limits the company’s ability to absorb fixed costs, fund development internally, and build a durable earnings base from its marketed therapies.

Advicenne SA (3MM) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.42M
Dividend Yield: ―
Average Volume (3M): 691
Price to Earnings (P/E): 216.8
Beta (1Y): 0.50
Revenue Growth: 0.10%
EPS Growth: 99.69%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Advicenne SA Business Overview & Revenue Model

Company Description

Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular...

Advicenne SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:3MM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ALSEN	45Neutral	EUR 87.32M	-2.16	-54.15%	―	―	6.26%
FR:ABNX	43Neutral	EUR 70.84M	-7.10	-80.82%	―	-10.38%	-72.05%
FR:SIGHT	43Neutral	EUR 18.98M	-1.00	52.39%	―	-610.31%	43.88%
FR:ALNEV	37Underperform	EUR 173.61K	0.00	-26.52%	―	-44.46%	100.00%

* Healthcare Sector Average

Performance Comparison

DE:3MM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:3MM	Advicenne SA	0.65	-1.04	-61.68%
FR:SIGHT	GenSight Biologics	0.07	-0.06	-45.11%
FR:ABNX	ABIONYX Pharma SA	1.57	-2.56	-62.00%
FR:ALSEN	Sensorion SAS	9.16	-7.94	-46.43%
FR:ALNEV	Neovacs SA	0.09	-341.91	-99.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Advicenne SA AI Stock Analysis